Akèy › Kansè pwostat › Arizona › Phoenix
Etid klinik pou Kansè pwostat nan Phoenix, AZ
17 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Phoenix (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Cancer Center at Saint Joseph's, Phoenix
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Mayo Clinic Hospital in Arizona, Phoenix
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Phoenix
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Ap rekriteFaz 3
- Research Site, Phoenix
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Ap rekriteFaz 1/2
- GSK Investigational Site, Phoenix
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- Mayo Clinic in Arizona - Phoenix ( Site 0044), Phoenix
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Ap rekriteFaz 3
- Mayo Clinic- Phoenix, Phoenix
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Ap rekriteFaz 3
- Research Site, Phoenix
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- Cancer Center at Saint Joseph's, Phoenix
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Mayo Clinic, Phoenix
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
- Mayo Clinic, Phoenix
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Ap rekriteFaz 2
- Mayo Clinic in Arizona, Phoenix
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Cancer Center at Saint Joseph's, Phoenix
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Mayo Clinic, Phoenix
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Ap rekriteFaz 2
- Cancer Center at Saint Joseph's, Phoenix
Understanding of Genetics by Men at Risk for Prostate Cancer
Ap rekriteVolontè an sante akeyi
- Mayo Clinic, Phoenix
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- Cancer Center at Saint Joseph's, Phoenix
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Phoenix
- Kansè nan tete25 etid
- Kansè kolorektal25 etid
- Obèsite22 etid
- Kansè Poumon ki pa ti selil20 etid
- Kansè Metastatik20 etid
- Ensifizyans kadyak18 etid
- Kansè (tout kalite)17 etid
- Myelom Miltip16 etid
- Kansè pankreyas16 etid
- Maladi kadyovaskilè16 etid
- Maladi Alzheimer15 etid
- Sipwa15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.